Developer docs
API playgroundTry for free, no card

Search company profiles

GondolaBio

Full company profile

uuid0000omk

Namestring
GondolaBio
Legal namestring
GondolaBio, LLC
Websiteurl
gondolabio.com
Company typeenum
Private
Founded yearint
2024
Descriptiontext

GondolaBio, LLC is a clinical-stage biopharmaceutical company founded in September 2024 as a spinout of BridgeBio Pharma, operating as a sister company under a decentralized subsidiary model. The company is headquartered in Palo Alto, California, and is led by Co-founder and CEO Neil Kumar, with Morgan Paull as COO, James Li as President, and Pete Schmidt as Chief Medical Officer of its affiliate Portal Therapeutics. GondolaBio is focused on developing disease-modifying therapeutics for patients with rare genetic diseases, with a stated emphasis on indications lacking approved treatments.

The company's lead asset is PORT-77, an oral small molecule inhibitor of the ABCG2 export protein designed to reduce plasma protoporphyrin IX (PPIX) concentrations in erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). Phase 2a GATEWAY results reported 79% plasma PPIX reduction in the high-dose cohort and 63% in the low-dose cohort with no serious adverse events, and the program has received FDA Orphan Drug and Fast Track Designations. Beyond PORT-77, the pipeline spans approximately 15 programs across indications including autosomal dominant polycystic kidney disease, alpha-1 antitrypsin deficiency, Charcot-Marie-Tooth 1A, neurofibromatosis type 1, hereditary pancreatitis, tuberous sclerosis complex, genetic epilepsies, and others, with an additional antisense oligonucleotide (ASO) discovery capability added via a partnership with the n-Lorem Foundation.

The business is pre-revenue and operates under a capital-intensive clinical development model, backed by a $300 million founding financing from Patient Square Capital, Viking Global Investors, and Frazier Life Sciences, with additional participation from Aisling Capital, Cormorant Asset Management, and Sequoia Capital. GondolaBio is organized into multiple wholly-owned subsidiaries (8 formed within the first 3 months of operation), each housing a discrete drug development program. Future commercialization is expected to follow a specialty pharma / orphan drug pricing model, with distribution through specialty pharmacies and rare disease specialists, and the company has already stood up an Expanded Access Program as pre-launch infrastructure.

Short descriptiontext

GondolaBio is a clinical-stage biopharmaceutical company developing disease-modifying therapeutics for rare genetic diseases, led by oral ABCG2 inhibitor PORT-77 for EPP and XLP, and operating a decentralized subsidiary model with 15+ pipeline programs as a spinout of BridgeBio Pharma.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersPalo Alto, United States
HQ citystring
Palo Alto
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease therapeutics, genetic disease medicines, small molecule inhibitors, clinical-stage biopharmaceuticals, orphan drug development
Industry2 codes
PRIMARYHLAAADAC
Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAJ
RNA Therapeutics Regulatory, Quality & Pharmacovigilance (GxP, comparability, post-market)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Pharmaceutical Preparations2834
Product category
Rare Disease Biopharmaceuticals
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Pre-revenue clinical stage company. Upon regulatory approval, the company plans to commercialize PORT-77 and other pipeline candidates for genetic diseases. Revenue model will likely follow specialty pharma pricing with orphan drug pricing premiums.

gondolabio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

GondolaBio is a clinical-stage biopharmaceutical company developing oral small molecule and antisense oligonucleotide (ASO) therapeutics for rare genetic diseases. The lead program, PORT-77, is an oral ABCG2 inhibitor in Phase 2 development for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), with a broader pipeline of 15+ programs spanning autosomal dominant polycystic kidney disease, alpha-1 antitrypsin deficiency, tuberous sclerosis complex, neurofibromatosis type 1, Charcot-Marie-Tooth 1A, and other genetic conditions. The company operates through a decentralized model with eight subsidiary companies, each housing an individual drug development program.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 79% plasma PPIX reduction in high-dose cohort (300mg BID)
+3 more records
Product overview1 text field

GondolaBio is a clinical-stage biopharmaceutical company developing breakthrough therapeutics for genetic diseases. The company's portfolio centers on PORT-77 as its lead program—an oral ABCG2 inhibitor for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP)—currently in Phase 2 development with Phase 2a results demonstrating 79% plasma PPIX reduction. The broader pipeline includes multiple genetic disease programs spanning discovery through IND-enabling stages, with a decentralized subsidiary model enabling parallel development of distinct therapeutic programs.

Product and service2 records
1PORT-77
CategoryLead clinical asset (oral small molecule)
Description

PORT-77 is an oral, small molecule ABCG2 inhibitor in Phase 2 development for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). It is designed to reduce plasma protoporphyrin IX (PPIX) concentrations by inhibiting ABCG2-mediated efflux from red blood cells and hepatocytes, with the goal of addressing skin phototoxicity and liver damage in EPP and XLP patients.

2Genetic Disease Pipeline
CategoryPipeline portfolio (genetic disease therapeutics)
Description

A diverse pipeline of 15+ drug development programs across multiple rare genetic diseases including autosomal dominant polycystic kidney disease, alpha-1 antitrypsin deficiency, Charcot-Marie-Tooth 1A, neurofibromatosis type 1, hereditary pancreatitis, tuberous sclerosis complex 1/2, genetic epilepsy driven by SynGAP1 mutations, Dup15q developmental epileptic encephalopathy, recurrent oxalate kidney stones, fibrous dysplasia, best vitelliform macular dystrophy, early onset preeclampsia, and 4 undisclosed programs.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1American Porphyrias Expert Collaborative (APEX)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-06-22
Description

Partnership for clinician webinar on PORT-77 Phase 2a GATEWAY study clinical data and disease-modifying potential in EPP.

financialcontent.com
2International Porphyria Network (IPNET)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-06-22
Description

Partnership for clinician webinar on PORT-77 clinical data.

financialcontent.com
3Global Porphyria Advocacy Coalition (GPAC)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-06-22
Description

Partnership for patient webinar to help the EPP community understand what the Phase 2a GATEWAY study means for them.

financialcontent.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-17
Description

Multi-collaboration agreement to discover novel antisense oligonucleotide (ASO) medicines for two prespecified biological targets in genetic diseases with significant unmet need. n-Lorem provides AI-informed ASO discovery platform and expertise; GondolaBio funds research and advances resulting therapies through clinical and commercial development via subsidiary companies. This partnership added the seventh and eighth subsidiaries to GondolaBio's portfolio.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-01
Description

GondolaBio was spun out from BridgeBio Pharma in September 2024 as a sister company, with three early-stage genetic disease assets transferred for development. GondolaBio leverages BridgeBio's decentralized model and drug development expertise.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight8 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Sister company and GondolaBio's parent at spinout; BridgeBio operates the same decentralized genetic-disease model and has commercialized rare-disease assets (e.g., Attruby for ATTR-CM). Direct operational and strategic peer given shared leadership lineage, capital structure philosophy, and target disease areas.

TypeDirect peer
Description

Leading antisense oligonucleotide (ASO) therapeutics company with multiple approved rare-disease drugs (Spinraza, Tegsedi, Wainua). Closely comparable to GondolaBio's ASO pipeline ambitions via its n-Lorem partnership given identical nucleic-acid modality and rare-disease focus.

TypeDirect peer
Description

RNA-targeted therapeutics leader with multiple approved rare-disease products (Onpattro, Givlaari, Oxlumo, Amvuttra). Comparable in modality (RNA therapeutics), commercial-stage rare-disease execution, and pipeline breadth targeting genetic diseases with high unmet need.

TypeBroad incumbent
Description

Established rare-disease biopharma with multiple approved genetic-disease products (Vimizim, Naglazyme, Voxzogo, Roctavian). Directly comparable target market (rare genetic diseases), specialty pharma commercialization model, and focus on disease-modifying treatments for underserved populations.

TypeDirect peer
Description

Clinical and commercial-stage rare-disease biotech with multiple approved products (Crysvita, Dojolvi, Mepsevii) and a pipeline targeting genetic conditions. Highly comparable decentralized development approach, orphan-disease focus, and similar small-molecule and biologic modality mix.

TypeBroad incumbent
Description

Genetic-disease specialty biopharma with approved treatments for Duchenne muscular dystrophy and expanding gene therapy franchise. Comparable in genetic-disease focus, specialty distribution model, and orphan-drug commercial strategy, though focused on neuromuscular conditions.

TypeBroad incumbent
Description

Large-cap biopharma with genetic-disease franchises in cystic fibrosis (Trikafta) and emerging programs in sickle cell disease, alpha-1 antitrypsin deficiency, and APOL1-mediated kidney disease — directly overlapping GondolaBio's A1AT and ADPKD programs.

TypeDirect peer
Description

Clinical-stage gene therapy biotech targeting rare genetic diseases (ABCC6, Hunter syndrome, Duchenne) with platform technology. Comparable in genetic-disease focus, clinical-stage profile, and orphan-drug regulatory strategy, though different modality (AAV gene therapy vs. small molecule/ASO).

TypeEmerging player
Description

Clinical-stage genetic-disease biotech developing treatments for Duchenne muscular dystrophy and other rare conditions. Comparable in clinical-stage profile, rare genetic-disease focus, and small-cap valuation trajectory, though narrower therapeutic area focus.

TypeEmerging player
Description

Clinical-stage biotech developing intracellular enzyme therapeutics for genetic diseases including Duchenne and myotonic dystrophy. Comparable in clinical-stage rare-disease positioning, platform approach to genetic diseases, and capital scale similar to GondolaBio's pre-IPO profile.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

GondolaBio

Rare Disease Biopharmaceuticalsgondolabio.com

GondolaBio is a clinical-stage biopharmaceutical company developing disease-modifying therapeutics for rare genetic diseases, led by oral ABCG2 inhibitor PORT-77 for EPP and XLP, and operating a decentralized subsidiary model with 15+ pipeline programs as a spinout of BridgeBio Pharma.

What GondolaBio does

GondolaBio, LLC is a clinical-stage biopharmaceutical company founded in September 2024 as a spinout of BridgeBio Pharma, operating as a sister company under a decentralized subsidiary model. The company is headquartered in Palo Alto, California, and is led by Co-founder and CEO Neil Kumar, with Morgan Paull as COO, James Li as President, and Pete Schmidt as Chief Medical Officer of its affiliate Portal Therapeutics. GondolaBio is focused on developing disease-modifying therapeutics for patients with rare genetic diseases, with a stated emphasis on indications lacking approved treatments.

The company's lead asset is PORT-77, an oral small molecule inhibitor of the ABCG2 export protein designed to reduce plasma protoporphyrin IX (PPIX) concentrations in erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). Phase 2a GATEWAY results reported 79% plasma PPIX reduction in the high-dose cohort and 63% in the low-dose cohort with no serious adverse events, and the program has received FDA Orphan Drug and Fast Track Designations. Beyond PORT-77, the pipeline spans approximately 15 programs across indications including autosomal dominant polycystic kidney disease, alpha-1 antitrypsin deficiency, Charcot-Marie-Tooth 1A, neurofibromatosis type 1, hereditary pancreatitis, tuberous sclerosis complex, genetic epilepsies, and others, with an additional antisense oligonucleotide (ASO) discovery capability added via a partnership with the n-Lorem Foundation.

The business is pre-revenue and operates under a capital-intensive clinical development model, backed by a $300 million founding financing from Patient Square Capital, Viking Global Investors, and Frazier Life Sciences, with additional participation from Aisling Capital, Cormorant Asset Management, and Sequoia Capital. GondolaBio is organized into multiple wholly-owned subsidiaries (8 formed within the first 3 months of operation), each housing a discrete drug development program. Future commercialization is expected to follow a specialty pharma / orphan drug pricing model, with distribution through specialty pharmacies and rare disease specialists, and the company has already stood up an Expanded Access Program as pre-launch infrastructure.

GondolaBio firmographics

Firmographics
Name
GondolaBio
Legal name
GondolaBio, LLC
Website
https://gondolabio.com
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
101–250 employees
Short description
GondolaBio is a clinical-stage biopharmaceutical company developing disease-modifying therapeutics for rare genetic diseases, led by oral ABCG2 inhibitor PORT-77 for EPP and XLP, and operating a decentralized subsidiary model with 15+ pipeline programs as a spinout of BridgeBio Pharma.
Ownership category
akta.pro rank

GondolaBio industry classification

Industry
Product category
Rare Disease Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAADAC
Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAJ
RNA Therapeutics Regulatory, Quality & Pharmacovigilance (GxP, comparability, post-market)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • Rare disease therapeutics
  • Genetic disease medicines
  • Small molecule inhibitors
  • Clinical-stage biopharmaceuticals
  • Orphan drug development

Where GondolaBio is headquartered

Location

Headquarters

HQ city
Palo Alto
HQ country
United States
HQ region
North America

Offices1 record

Markets served

GondolaBio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Pharmaceutical Product Sales: Pre-revenue clinical stage company. Upon regulatory approval, the company plans to commercialize PORT-77 and other pipeline candidates for genetic diseases. Revenue model will likely follow specialty pharma pricing with orphan drug pricing premiums.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

GondolaBio product offering

Product offering

Core offering

GondolaBio is a clinical-stage biopharmaceutical company developing oral small molecule and antisense oligonucleotide (ASO) therapeutics for rare genetic diseases. The lead program, PORT-77, is an oral ABCG2 inhibitor in Phase 2 development for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), with a broader pipeline of 15+ programs spanning autosomal dominant polycystic kidney disease, alpha-1 antitrypsin deficiency, tuberous sclerosis complex, neurofibromatosis type 1, Charcot-Marie-Tooth 1A, and other genetic conditions. The company operates through a decentralized model with eight subsidiary companies, each housing an individual drug development program.

Product overview

GondolaBio is a clinical-stage biopharmaceutical company developing breakthrough therapeutics for genetic diseases. The company's portfolio centers on PORT-77 as its lead program—an oral ABCG2 inhibitor for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP)—currently in Phase 2 development with Phase 2a results demonstrating 79% plasma PPIX reduction. The broader pipeline includes multiple genetic disease programs spanning discovery through IND-enabling stages, with a decentralized subsidiary model enabling parallel development of distinct therapeutic programs.

Differentiator

Problem solved

Functional benefit

Products and services

  • PORT-77 PORT-77 is an oral, small molecule ABCG2 inhibitor in Phase 2 development for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). It is designed to reduce plasma protoporphyrin IX (PPIX) concentrations by inhibiting ABCG2-mediated efflux from red blood cells and hepatocytes, with the goal of addressing skin phototoxicity and liver damage in EPP and XLP patients.
  • Genetic Disease Pipeline A diverse pipeline of 15+ drug development programs across multiple rare genetic diseases including autosomal dominant polycystic kidney disease, alpha-1 antitrypsin deficiency, Charcot-Marie-Tooth 1A, neurofibromatosis type 1, hereditary pancreatitis, tuberous sclerosis complex 1/2, genetic epilepsy driven by SynGAP1 mutations, Dup15q developmental epileptic encephalopathy, recurrent oxalate kidney stones, fibrous dysplasia, best vitelliform macular dystrophy, early onset preeclampsia, and 4 undisclosed programs.

Quantifiable outcome

  • 79% plasma PPIX reduction in high-dose cohort (300mg BID)
  • +3 more outcomes

Companies that use GondolaBio

Customer profile

Segments1 record

Ideal customer profiles1 record

GondolaBio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

GondolaBio partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered minor and core.

  • American Porphyrias Expert Collaborative (APEX)minorStrategic or Co-development Partner · 22 June 2026Partnership for clinician webinar on PORT-77 Phase 2a GATEWAY study clinical data and disease-modifying potential in EPP.
  • International Porphyria Network (IPNET)minorStrategic or Co-development Partner · 22 June 2026Partnership for clinician webinar on PORT-77 clinical data.
  • Global Porphyria Advocacy Coalition (GPAC)minorStrategic or Co-development Partner · 22 June 2026Partnership for patient webinar to help the EPP community understand what the Phase 2a GATEWAY study means for them.
  • n-Lorem FoundationcoreStrategic or Co-development Partner · 17 December 2024Multi-collaboration agreement to discover novel antisense oligonucleotide (ASO) medicines for two prespecified biological targets in genetic diseases with significant unmet need. n-Lorem provides AI-informed ASO discovery platform and expertise; GondolaBio funds research and advances resulting therapies through clinical and commercial development via subsidiary companies. This partnership added the seventh and eighth subsidiaries to GondolaBio's portfolio.
  • BridgeBio PharmacoreStrategic or Co-development Partner · 1 September 2024GondolaBio was spun out from BridgeBio Pharma in September 2024 as a sister company, with three early-stage genetic disease assets transferred for development. GondolaBio leverages BridgeBio's decentralized model and drug development expertise.

Scale indicators4 records

Recent moves7 records

Expansion highlights8 records

GondolaBio competitors and assessment

Company assessment

Direct peers

  • BridgeBio Pharma: Sister company and GondolaBio's parent at spinout; BridgeBio operates the same decentralized genetic-disease model and has commercialized rare-disease assets (e.g., Attruby for ATTR-CM). Direct operational and strategic peer given shared leadership lineage, capital structure philosophy, and target disease areas.
  • Ionis Pharmaceuticals: Leading antisense oligonucleotide (ASO) therapeutics company with multiple approved rare-disease drugs (Spinraza, Tegsedi, Wainua). Closely comparable to GondolaBio's ASO pipeline ambitions via its n-Lorem partnership given identical nucleic-acid modality and rare-disease focus.
  • Alnylam Pharmaceuticals: RNA-targeted therapeutics leader with multiple approved rare-disease products (Onpattro, Givlaari, Oxlumo, Amvuttra). Comparable in modality (RNA therapeutics), commercial-stage rare-disease execution, and pipeline breadth targeting genetic diseases with high unmet need.
  • Ultragenyx Pharmaceutical: Clinical and commercial-stage rare-disease biotech with multiple approved products (Crysvita, Dojolvi, Mepsevii) and a pipeline targeting genetic conditions. Highly comparable decentralized development approach, orphan-disease focus, and similar small-molecule and biologic modality mix.
  • Regenxbio: Clinical-stage gene therapy biotech targeting rare genetic diseases (ABCC6, Hunter syndrome, Duchenne) with platform technology. Comparable in genetic-disease focus, clinical-stage profile, and orphan-drug regulatory strategy, though different modality (AAV gene therapy vs. small molecule/ASO).

Broad incumbents

  • BioMarin Pharmaceutical: Established rare-disease biopharma with multiple approved genetic-disease products (Vimizim, Naglazyme, Voxzogo, Roctavian). Directly comparable target market (rare genetic diseases), specialty pharma commercialization model, and focus on disease-modifying treatments for underserved populations.
  • Sarepta Therapeutics: Genetic-disease specialty biopharma with approved treatments for Duchenne muscular dystrophy and expanding gene therapy franchise. Comparable in genetic-disease focus, specialty distribution model, and orphan-drug commercial strategy, though focused on neuromuscular conditions.
  • Vertex Pharmaceuticals: Large-cap biopharma with genetic-disease franchises in cystic fibrosis (Trikafta) and emerging programs in sickle cell disease, alpha-1 antitrypsin deficiency, and APOL1-mediated kidney disease — directly overlapping GondolaBio's A1AT and ADPKD programs.

Emerging players

  • Solid Biosciences: Clinical-stage genetic-disease biotech developing treatments for Duchenne muscular dystrophy and other rare conditions. Comparable in clinical-stage profile, rare genetic-disease focus, and small-cap valuation trajectory, though narrower therapeutic area focus.
  • Entrada Therapeutics: Clinical-stage biotech developing intracellular enzyme therapeutics for genetic diseases including Duchenne and myotonic dystrophy. Comparable in clinical-stage rare-disease positioning, platform approach to genetic diseases, and capital scale similar to GondolaBio's pre-IPO profile.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

GondolaBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

GondolaBio leadership team

Management profile

Number of profiles

Profiles4 records

GondolaBio subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

GondolaBio funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

GondolaBio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GondolaBio

What does GondolaBio do?

GondolaBio is a clinical-stage biopharmaceutical company developing oral small molecule and antisense oligonucleotide (ASO) therapeutics for rare genetic diseases. The lead program, PORT-77, is an oral ABCG2 inhibitor in Phase 2 development for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), with a broader pipeline of 15+ programs spanning autosomal dominant polycystic kidney disease, alpha-1 antitrypsin deficiency, tuberous sclerosis complex, neurofibromatosis type 1, Charcot-Marie-Tooth 1A, and other genetic conditions. The company operates through a decentralized model with eight subsidiary companies, each housing an individual drug development program.

Is GondolaBio a public or private company?

GondolaBio is a private company. It is classified as venture growth investor backed and is currently operating.

When was GondolaBio founded?

GondolaBio was founded in 2024. It employs 101 to 250 people.

Where is GondolaBio based?

GondolaBio is headquartered in Palo Alto, United States, in the North America region.

How does GondolaBio make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are GondolaBio's main competitors?

Direct peers on record are BridgeBio Pharma, Ionis Pharmaceuticals, Alnylam Pharmaceuticals, Ultragenyx Pharmaceutical and Regenxbio. Broad incumbents are BioMarin Pharmaceutical, Sarepta Therapeutics and Vertex Pharmaceuticals. Emerging players are Solid Biosciences and Entrada Therapeutics.

Does GondolaBio have an API?

No public API is recorded for GondolaBio.

What industry is GondolaBio in?

GondolaBio's product category is Rare Disease Biopharmaceuticals. Its primary akta.pro industry code is HLAAADAC, Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown), with a secondary code of HLAAADAJ, RNA Therapeutics Regulatory, Quality & Pharmacovigilance (GxP, comparability, post-market). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceBioSpace 40 Under 40 winners Paull, Zhang let patients with rare disease lead the way at BridgeBioMorgan Paull and Christine Zhang, leaders at BridgeBio, were named to BioSpace's 2026 40 Under 40 list. Zhang's Evanesco Therapeutics aims to develop an amyloid depleter for ATTR-CM, targeting disease reversal, while Paull's GondolaBio focuses on rare diseases like hereditary pancreatitis. Both companies operate under BridgeBio's hub-and-spoke model.Business Wire BlogGondolaBio and Children’s Tumor Foundation Announce Partnership to Advance GondolaBio’s Neurofibromatosis Type 1 ProgramGondolaBio and Children's Tumor Foundation announced a partnership to advance GondolaBio's preclinical neurofibromatosis type 1 program, with CTF providing guidance and receiving an equity interest. The collaboration aims to incorporate patient and family perspectives into development. NF1 affects about 1 in 2,500 births worldwide.FinancialContent Business PageGondolaBio and Children’s Tumor Foundation Announce Partnership to Advance GondolaBio’s Neurofibromatosis Type 1 ProgramGondolaBio and the Children's Tumor Foundation announced a partnership to advance GondolaBio's preclinical neurofibromatosis type 1 program. CTF will provide guidance and receive an equity interest in the program. The collaboration aims to incorporate patient and family perspectives into development.Clinical Trials ArenaGondolaBio reports positive data from Phase IIa trial of PORT-77GondolaBio reported positive Phase IIa trial results for PORT-77, an ABCG2 inhibitor for EPP and XLP, showing mean 79% and 63% reductions in plasma PPIX at 300mg BID and 180mg QD, respectively. The trial was well tolerated with no serious adverse events. GondolaBio plans to start the global Phase IIb/III PATHWAY trial in Q3 2026.AInvestGondolaBio 79% Win: Why Phase 2a Is Not a Valuation BridgeGondolaBio announced Phase 2a results for PORT-77 showing a 79% reduction in plasma protoporphyrin IX in patients with erythropoietic protoporphyria, a rare genetic disorder causing pain upon sunlight exposure. The article argues that this positive biomarker readout is directionally encouraging but represents only an early proof-of-concept, with three to five years of clinical development, regulatory approval, and safety validation still required before any commercial viability. The author cautions that investors should focus on cash runway, Phase 2b dose design, comparator safety data, and binary failure risks at each development stage rather than reacting to the headline percentage.FinancialContent Business PageGondolaBio Announces Positive Phase 2a Results Demonstrating 79% Plasma Protoporphyrin IX Reduction and Disease-Modifying Potential of PORT-77 for Erythropoietic ProtoporphyriaGondolaBio announced positive results from its Phase 2a GATEWAY trial of PORT-77 in patients with erythropoietic protoporphyria (EPP), meeting the primary endpoint with a mean 79% plasma PPIX reduction in the high-dose cohort and 63% in the low-dose cohort. The drug was well tolerated with no serious adverse events or treatment discontinuations, and the company plans to initiate the Phase 2b/3 PATHWAY trial in Q3 2026 following an End-of-Phase 2 meeting with the FDA. EPP and XLP affect over 25,000 people in the U.S. and EU and currently have no approved disease-modifying treatments available.BioSpaceGondolaBio Announces Positive Phase 2a Results Demonstrating 79% Plasma Protoporphyrin IX Reduction and Disease-Modifying Potential of PORT-77 for Erythropoietic ProtoporphyriaGondolaBio announced positive Phase 2a results for PORT-77 in erythropoietic protoporphyria, showing a mean plasma PPIX reduction of 79% at the high dose and 63% at the low dose. The drug was well tolerated with no serious adverse events, and the company plans to initiate the Phase 2b/3 PATHWAY trial in Q3 2026.Business Wire BlogGondolaBio Announces Positive Phase 2a Results Demonstrating 79% Plasma Protoporphyrin IX Reduction and Disease-Modifying Potential of PORT-77 for Erythropoietic ProtoporphyriaGondolaBio announced positive Phase 2a results for PORT-77 in erythropoietic protoporphyria, showing a mean 79% plasma PPIX reduction at high dose and 63% at low dose. The drug was well tolerated with no serious adverse events, and the company plans to initiate the Phase 2b/3 PATHWAY trial in Q3 2026.PorphyrianewsPORT-77 gets 2 FDA designations as treatment for EPP and XLPPORT-77, an oral small molecule therapy developed by Gondolabio through its affiliate Portal Therapeutics, has received orphan drug and fast track designations from the U.S. FDA for the treatment of erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). These designations will support the development of PORT-77, which potentially offers disease-modifying effects by reducing skin and liver damage associated with these conditions. The company is advancing this program through collaborations with the FDA, highlighting the urgent need for effective treatments for individuals affected by these rare diseases.BioSpaceGondolaBio Receives U.S. FDA Orphan Drug and Fast Track Designations for PORT-77 for the Treatment of Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP)GondolaBio announced that the U.S. FDA granted Orphan Drug Designation and Fast Track Designation to its affiliate Portal Therapeutics for PORT-77, an investigational oral small molecule ABCG2 inhibitor for treating Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP). The therapy is currently in a Phase 2A proof-of-concept trial called GATEWAY, with primary endpoint of plasma PPIX reduction, and has demonstrated significant PPIX reduction within hours with no serious adverse events identified in preclinical and Phase 1 studies. EPP and XLP affect more than 25,000 people in the U.S. and EU, with approximately 20-30% of patients experiencing liver damage and no approved disease-modifying treatments currently available.